Baddeley, A. D., & Hitch, G. (1974). Working memory. In G.H. Bower (Ed.), The psychology of learning and motivation: Advances in research and theory (Vol. 8, pp. 47–89). New York: Academic Press.
It's for the course "Psychology of Memory And Thinking". I have an exam this Sunday. I'm currently at third chapter (page 33).
The advantage to WILT 2.0 is that it shouldn't give healthy stem cells the division limit, since you're not deleting the telomerase gene. They would remain largely unaffected since they express telomerase at much lower levels compared to cancer cells. No need for super difficult stem cell replacement therapies for the gut, skin, blood, and lungs. See Aubrey talk about it here
The post title is from here:
https://maiabiotech.com/programs/thio/
THIO is a Telomere-by-Telomerase Targeting Agent in Development
THIO (aka 6-thio-dG, 6-thio-2’-deoxyguanosine) is a first-in-class small molecule that is the only telomere-by-telomerase targeting agent currently in development. THIO selectively kills cancer cells by modifying telomeric DNA structure and function utilizing the enzyme telomerase.
Telomerase is present in >85% of human cancers and contributes significantly to the proliferation and reproductive immortality of cancer cells. THIO’s activity was shown to be cancer-specific in tumor types with active telomerase.
A New Therapeutic Strategy
THIO is recognized by telomerase and incorporated into telomeres selectively in cancer cells. Once incorporated, THIO compromises the telomere structure and function, leading to ‘uncapping’ of the chromosome ends and thus resulting in rapid tumor cell death. Low doses of THIO, followed by anti-PD-L1 or anti-PD1 therapy, completely eliminated advanced tumors in preclinical models and produced cancer cell specific immune memory, where the immune system continued to be active against the cancer cells after extended periods of time, with no additional treatment. These results demonstrate how the THIO-produced telomere stress increases innate sensing and adaptive anti-tumor immunity, which provides a strong rationale for sequentially combining telomere-targeted therapy with immunotherapy (Mender et al., 2020).
MAIA is advancing THIO in a Phase 1/2 clinical study in Non-Small Cell Lung Cancer (NSCLC). This will be the first study to test THIO’s immune system activation followed by administration of the checkpoint inhibitor Libtayo®, allowing for the immune activation and PD-1 sensitivity to take effect. The trial will test the hypothesis that lower doses of THIO administered prior to Libtayo treatment would enhance and prolong responses in subjects with advanced NSCLC who did not respond or progressed after first-line treatment with a checkpoint inhibitor.
THIO followed by
... keep reading on reddit ➡
Hi all,
Considering that corporate support & employee engagement/employee willingness are two independent variables - which models can be used to support/explain the above-given independent variables [1 model to support each independent variable]
Additionally, are there any other independent variables [which have sufficient indicators] that can be suggested for this topic?
Any help is appreciated and thank you in advance
